Navigation Links
Moody's Upgrades Mylan
Date:3/11/2011

PITTSBURGH, March 11, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today reported that Moody's Investors Service ("Moody's") has upgraded the company's credit ratings, including the "Corporate Family Rating," to Ba2 from Ba3 (positive outlook). Following this action, Moody's rating outlook is stable.  

According to Moody's: "Moody's upgrade of Mylan reflects improving earnings trends accomplished through new product launches, a strong global generics footprint, and good vertical integration… Mylan's Ba2 Corporate Family Rating continues to reflect good size and scale as the #3 player in the global generics pharmaceutical industry, a solid global generic drug pipeline, and revenue diversity from the specialty branded segment."

Mylan's Chief Financial Officer John Sheehan commented: "Moody's upgrade of Mylan's credit ratings follows a similar positive upgrade by S&P yesterday. We are gratified that independent third parties such as these ratings agencies recognize the strength of Mylan's diversified business and favorable position within the generics industry, as well as the company's continued potential for growth."

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking statements," including with regard to the company's anticipated growth. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Smart Sense(TM) From RF Technologies Upgrades Safe Place(R) Bracelets Using Industry-Leading Infant Security Technology, Fit and Comfort
2. Abbott to Feature Novel Tests and New Upgrades to Testing Platforms at American Association for Clinical Chemistry Lab Expo
3. TeleTracking Upgrades Best-selling TransferCenter™ Software
4. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
5. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
6. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
7. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
8. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
9. Mylan Receives Approval for Generic Version of GoLytely(R)
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  Echo Therapeutics, Inc. ... company focused on non-invasive continuous glucose monitoring ... announced that it will host a webcast ... 2015 at 9:00 a.m. Eastern Time to ... corporate strategy, advancements in its CGM system, ...
(Date:2/8/2016)... historic vote among its members this weekend, the Shinnecock Indian Nation voted ... dispensary on tribal land near Southampton . ... patients in the state,s Medical Cannabis Program. --> ... the state,s Medical Cannabis Program. --> Tribal members voted ... from the State of New York as a ...
(Date:2/8/2016)... Switzerland and PALO ALTO, Calif. , Feb. ... and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical ... of retinal disease, announced today agreements for the clinical ... will manufacture material at multiple sites, including Slough (UK), ... --> --> Retinal diseases, such as ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... will ensure lab personnel have a basic understanding of the techniques they use ... Enhanced understanding will help them reduce waste and rework to create a leaner ...
(Date:2/9/2016)... ... February 09, 2016 , ... Sir Grout, the leading ... proud to announce that many of their franchises have received the Super Service ... surface restoration franchises received customer recognition through positive reviews and testimonials, as well ...
(Date:2/8/2016)... ... , ... CURE Media Group , the nation’s leading digital and print ... Awards event , which will annually honor individuals making heroic contributions in the field ... MM Heroes Awards nomination process is officially open through February 17 for patients, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert ... the beginning of a new charity campaign. As part of their ongoing community ... (CASA). In the belief that children deserve a voice, and in the spirit ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
Breaking Medicine News(10 mins):